

Zenith™

Amniotic Membrane Allograft

2024

Reimbursement Guide



Distributed by:

LM
LEGACY MEDICAL
CONSULTANTS

Reimbursement Disclaimer

Legacy Medical Consultants ("Legacy") provides this guide for educational/informational purposes only and it is subject to change without notice. This guide is not an affirmative instruction as to which codes and modifiers to use for a particular service, supply, procedure or treatment and does not constitute advice regarding coding, coverage, or payment for any Legacy product. It is the responsibility of providers, physicians and clinicians to determine and submit appropriate codes, charges and modifiers for products, services, supplies, procedures, or treatment furnished or rendered. Providers, physicians and clinicians should contact their payers for specific and current information on their coding, coverage, and payment policies. The information provided here is without any other warranty or guarantee of any kind, expressed or implied, as to completeness, accuracy, or otherwise. All rates shown are national average Medicare rates, have not been adjusted for geographic variations in payment or other factors, such as sequestration, and are subject to change without notice.

For further detailed product information, including indications for use, contraindications, effects, precautions and warnings, please consult the product's Instructions for Use (IFU) prior to use.

General Reimbursement and Coding

Reimbursement and coverage eligibility for the use of Zenith™ Amniotic Membrane and associated procedures varies by Medicare and Private Payers. Coverage policies, prior authorizations, contract terms, billing edits, and site of service influence reimbursement.

Place of Service (POS) Codes

POS codes are 2-digit numbers included on health care professional claims to indicate the setting in which a service was provided. The Centers for Medicare and Medicaid Services (CMS) maintain POS codes used throughout the healthcare industry. Based on the payer, setting and patient status, the product may be billed on the physician's claim form along with professional charges or it may be billed to a client or facility. Listed below are POS and descriptions that typically apply to our products. These codes should be used on professional claims to specify the entity where service(s) were rendered. Check with individual payors for reimbursement policies regarding these codes. Please see payor specific reimbursement policies where the product may be billed differently (e.g., part of consolidated billing for Medicare Part A as a facility charge vs. separately on a physician claim form).

Place of Service Code 11 – Office

(Location other than a hospital, skilled nursing facility (SNF), military treatment facility, community health center, State or Local public health clinic, or intermediate care facility (ICF), where the health professional routinely provides health examinations, diagnosis, and treatment of illness or injury on an ambulatory basis.)

Place of Service Code 12 – Home

(Location, other than a hospital or other facility, where the patient receives care in a private residence.)

Place of Service Code 32 – Nursing Facility

(A facility which primarily provides to residents skilled nursing care and related services for the rehabilitation of injured, disabled, or sick persons, or, on a regular basis, health-related care services above the level of custodial care to other than individuals with intellectual disabilities.)

The above POS codes represent locations where physician claim form would include the Amniotic Membrane product charge. Based on the payer, setting and patient status, the product may be billed on the physician's claim form along with professional charges or it may be billed to a client or facility.

General Reimbursement and Coding

CPT® Coding

The Current Procedural Terminology (CPT) code set describes medical, surgical, and diagnostic services and is designed to communicate uniform information about medical services and procedures among physicians, coders, patients, accreditation organizations, and payers for administrative, financial, and analytical purposes. The codes are for the professional services and that the supply of skin substitute graft(s) is reported separately.

CPT®	DESCRIPTIONS FOR APPLICATION OF SKIN SUBSTITUTES
15271	Application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area
+15272	Each additional 25 sq. cm up to 100 sq. cm wound surface area, or part thereof. List separately in addition to code 15271 for primary procedure.
15273	Application of skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq. cm; first 100 sq. cm wound surface area, or 1% of body area of infants and children
+15274	Each additional 100 sq. cm wound surface area or part thereof, or each additional 1% of body area of infants and children or part thereof. List separately in addition to code 15273 for primary procedure.
15275	Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq. cm; first 25 sq. cm or less wound surface area
+15276	Each additional 25 sq. cm wound surface area, or part thereof. List separately in addition to code 15275 for primary procedure.
15277	Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq. cm; first 100 sq. cm wound surface area, or 1% of body area of infants
+15278	Each additional 100 sq. cm wound surface area or part thereof, or each additional 1% of body area for infants and children, or part thereof. Use in conjunction with primary procedure code 15277.

CPT® Codes 15271-15278:

- Billing Units = 1 unit per service for CPT® 15271, 15273, 15275 and 15277 (daily limitations apply)
- Add-on codes 15272, 15274, 15276 and 15278 are billed as 1 unit for each additional amount of graft material as specified; either each additional 25 sq. cm or 100 sq. cm applied. The units are determined by the location and size of the defect. For multiple wounds, sum the surface area of all wounds from all anatomic sites that are grouped together into the same code descriptor. Do not sum wounds from different groupings of anatomic sites (e.g., face and arms).

Add-on Codes: The + symbol signifies an add-on code. An add-on code cannot be used alone but must be billed with the initial code above it. Please check the CPT® 2024 coding book for further instructions.

Review the Appropriate Wastage Modifiers: When there isn't any product wastage, append the JZ modifier to the HCPCS code. When a portion of the graft is wasted, append the JW modifier to the line item with the HCPCS code noting the amount discarded. Visit <https://tinyurl.com/v69xybdd> or <https://tinyurl.com/ytrymt25> for more information.

General Reimbursement and Coding

ICD-10® Codes

It is recommended that providers select the most specific primary and secondary diagnosis codes to accurately describe the reason the wound is not healing properly, and codes that indicate the wound is chronic and describe the location, severity, and laterality (for lower extremity ulcers).

Example of specific Diabetic Foot Ulcers (DFUs) codes:

- Primary diagnosis: E11.621, type 2 diabetes mellitus with a foot ulcer
- Secondary diagnosis: L97.522, non-pressure chronic ulcer of other part of left foot with fat layer exposed

Example of specific Venous Leg Ulcers (VLUs) codes:

- Primary diagnosis: I87.312, chronic venous hypertension (idiopathic) with ulcer of left lower extremity
- Secondary diagnosis: L97.222, non-pressure chronic ulcer of left calf with fat layer exposed

Important Billing Instructions

Zenith Amniotic Membrane (Q4253) is included on the Medicare Part B Average Sales Price (ASP) Drug Pricing File published quarterly by the Centers for Medicare and Medicaid Services (CMS)

- Average Sales Price information is published quarterly by the Centers for Medicare and Medicaid Services (CMS) in the ASP Medicare Part B Drug Pricing File or Not Otherwise Classified (NOC) Pricing File. Providers are encouraged to review the ASP Pricing files posted quarterly by CMS and listed by HCPCS on CMS.gov for updates.
- Payment allowance limits that are not included in the ASP Medicare Part B Drug Pricing File or Not Otherwise Classified (NOC) Pricing File, are based on the published Wholesale Acquisition Cost (WAC) or invoice pricing. In determining the payment limit based on WAC, the contractors follow the methodology specified in Publication. 100-04, Chapter 17, Drugs and Biologicals, for calculating the Average Wholesale Price (AWP), but substitute WAC for AWP.
- Providers are encouraged to check with their local MACs for information on established rates
- Providers are also encouraged to check with payers to determine if an invoice is required to be submitted with the claim and/or in Box 19 of the CMS-1500 claim form.
- Providers should check with local payers regarding appropriate use of modifiers.

Physicians should report all surgical and medical services performed, and are responsible for determining which CPT® code(s) accurately represent the services performed.

Procedure Codes for Application of Skin Graft Substitutes References

CPT® CODE ²	DESCRIPTION
15271	App of skin sub to trunk, arms, legs, up to 100 sq. cm; first 25 sq. cm
+15272	Each additional 25 sq. cm
15273	App of skin sub to trunk, arms, legs to > 100 sq. cm, 1 st 100 sq. cm
+15274	Each additional 100 sq. cm
15275	App of skin sub to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, multiple digits up to 100 sq. cm; 1 st 25 sq. cm
+15276	Each additional 25 sq. cm
15277	App of skin sub to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, multiple digits 100 sq. cm
+15278	Each additional 100 sq. cm

Coinsurance/Deductibles:

As with all products and services paid for under Medicare Part B, Medicare will reimburse 80 percent of the allowable amount. The patient, or secondary/supplemental plan, is responsible for the remaining 20 percent coinsurance amount. The appropriate annual deductibles also apply.

Sequestration:

Since April 1, 2013, all Medicare claims with a date-of-service on or after April 1, 2013 are subjected to a 2 percent sequestration amount. Please note, the 2 percent is deducted from the 80 percent allowable amount paid by Medicare and not the coinsurance amount.

Geographic Practice Cost Index (GPCI):

The Medicare physician fee schedule amounts are adjusted to reflect the variation in practice costs from area to area. A GPCI has been established for every Medicare payment locality based on the RVUs for work, practice expense, and malpractice. The GPICs are applied in the calculation of a fee schedule payment amount by multiplying the RVU for each component times the GPCI for that component.

Legacy provides this guide for educational/ informational purposes only and it is subject to change without notice. This guide is not an affirmative instruction as to which codes and modifiers to use for a particular service, supply, procedure or treatment and does not constitute advice regarding coding, coverage, or payment for any Legacy product. The information provided here is without any other warranty or guarantee of any kind, expressed or implied, as to completeness, accuracy, or otherwise. All rates shown are national average Medicare rates, have not been adjusted for geographic variations in payment or other factors, such as sequestration, and are subject to change without notice.

Common ICD-10-CM Diagnosis Code Reference

The following chart provides some of the common diagnoses and ICD-10-CM codes that may require skin substitute grafts as a treatment option. This partial list is provided only for reference and does not represent any particular case or suggested treatment. Not all options are presented here, and the provider is always responsible for the assignment of the actual diagnosis codes as documented in the medical record.

CODE	DESCRIPTION (These are common codes, not an exhaustive list.)
DIABETIC ULCER CODES	
E08.621	Diabetes mellitus due to underlying condition with foot ulcer
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer
E10.621	Type 1 diabetes mellitus with foot ulcer
E10.622	Type 1 diabetes mellitus with other skin ulcer
E11.621	Type 2 diabetes mellitus with foot ulcer
E11.622	Type 2 diabetes mellitus with other skin ulcer
E13.621	Other specified diabetes mellitus with foot ulcer
E13.622	Other specified diabetes mellitus with other skin ulcer
VARICOSE VEINS OF LOWER EXTREMITY	
I83.012	Varicose veins of right lower extremity with ulcer of calf
I83.013	Varicose veins of right lower extremity with ulcer of ankle
I83.014	Varicose veins of right lower extremity with ulcer of heel and midfoot
I83.015	Varicose veins of right lower extremity with ulcer other part of foot
I83.018	Varicose veins of right lower extremity with ulcer other part of lower leg
I83.022	Varicose veins of left lower extremity with ulcer of calf
I83.023	Varicose veins of left lower extremity with ulcer of ankle
I83.024	Varicose veins of left lower extremity with ulcer of heel and midfoot
I83.025	Varicose veins of left lower extremity with ulcer other part of foot
I83.028	Varicose veins of left lower extremity with ulcer other part of lower leg
POSTTHROMBOTIC SYNDROME LOWER EXTREMITY	
I87.011	Postthrombotic syndrome with ulcer of right lower extremity
I87.012	Postthrombotic syndrome with ulcer of left lower extremity
I87.013	Postthrombotic syndrome with ulcer of bilateral lower extremity
CHRONIC VENOUS HYPERTENSION OF LOWER EXTREMITY	
I87.311	Chronic venous hypertension (idiopathic) with ulcer of right lower extremity
I87.312	Chronic venous hypertension (idiopathic) with ulcer of left lower extremity
I87.313	Chronic venous hypertension (idiopathic) with ulcer of bilateral lower extremity

Common ICD-10-CM Diagnosis Code Reference

(Continued)

CODE	DESCRIPTION (These are common codes, not an exhaustive list.)
NON-PRESSURE CHRONIC ULCER OF LOWER LIMB	
L97.311	Non-pressure chronic ulcer of right ankle limited to breakdown of skin
L97.312	Non-pressure chronic ulcer of right ankle with fat layer exposed
L97.321	Non-pressure chronic ulcer of left ankle limited to breakdown of skin
L97.322	Non-pressure chronic ulcer of left ankle with fat layer exposed
L97.411	Non-pressure chronic ulcer of right heel and midfoot limited to breakdown of skin
L97.412	Non-pressure chronic ulcer of right heel and midfoot with fat layer exposed
L97.421	Non-pressure chronic ulcer of left heel and midfoot limited to breakdown of skin
L97.422	Non-pressure chronic ulcer of left heel and midfoot with fat layer exposed
L97.511	Non-pressure chronic ulcer of other part of right foot limited to breakdown of skin
L97.512	Non-pressure chronic ulcer of other part of right foot with fat layer exposed
L97.521	Non-pressure chronic ulcer of other part of left foot limited to breakdown of skin
L97.522	Non-pressure chronic ulcer of other part of left foot with fat layer exposed
L97.811	Non-pressure chronic ulcer of other part of right lower leg limited to breakdown of skin
L97.812	Non-pressure chronic ulcer of other part of right lower leg with fat layer exposed
L97.821	Non-pressure chronic ulcer of other part of left lower leg limited to breakdown of skin
L97.822	Non-pressure chronic ulcer of other part of left lower leg with fat layer exposed
L97.211	Non-pressure chronic ulcer of right calf limited to breakdown of skin
L97.212	Non-pressure chronic ulcer of right calf with fat layer exposed
L97.221	Non-pressure chronic ulcer of left calf limited to breakdown of skin
L97.222	Non-pressure chronic ulcer of left calf with fat layer exposed

Advanced Therapy Documentation Considerations

Prior to requesting insurance verification or prior authorization from a payer or submitting a claim for an advanced wound healing product, the provider should verify applicable coverage and documentation requirements with the payor.

Common criteria and documentation elements required of payors include the following in the patient's medical record:

- Determine the Medical Necessity
- Duration of ulcer
- Location of ulcer
- Whether the ulcer has failed to respond to conservative measures
- Baseline measurements of the ulcer
- If applicable, describe the treatment of the underlying disease process contributing to the ulcer
- Indicate the appropriate patient diagnosis codes
- Status of the wound, including (as applicable) presence or absence of cellulitis, infection, tunnels, tracts, eschar, or necrotic material
- Extent of the ulcer (e.g., dermis, involvement of tendon, muscle, capsule, or bone, etc.)
- For diabetic foot ulcers, whether the patient exhibits neuropathy
- Evaluation of venous sufficiency / insufficiency ulcers
- Whether the patient is competent, and/or has the support services necessary to participate in follow-up-care

Claim Forms

Sample CMS 1500 Paper Claim Form



HEALTH INSURANCE CLAIM FORM

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

☐ PICA		☐ PICA	
1. MEDICARE ☒ MEDICAID ☐ TRICARE ☐ CHAMPVA ☐ GROUP HEALTH PLAN ☐ FECA BOX (UNG) ☐ OTHER ☐		1a. INSURED'S I.D. NUMBER (For Program in Item 1) 123-45-6789A	
2. PATIENT'S NAME (Last Name, First Name, Middle Initial) Doe, John A.		3. PATIENT'S BIRTH DATE MM DD YY SEX 06 22 1945 M ☒ X ☐ F	
4. INSURED'S NAME (Last Name, First Name, Middle Initial) Doe, John A.		5. INSURED'S ADDRESS (No., Street) 123 Street St	
6. PATIENT RELATIONSHIP TO INSURED Self ☒ Spouse ☐ Child ☐ Other ☐		7. INSURED'S ADDRESS (No., Street) 123 Street St	
8. RESERVED FOR NUCC USE		9. INSURED'S POLICY GROUP OR FECA NUMBER	
10. IS PATIENT'S CONDITION RELATED TO: a. EMPLOYMENT? (Current or Previous) ☐ YES ☒ NO b. AUTO ACCIDENT? ☐ YES ☒ NO c. OTHER ACCIDENT? ☐ YES ☒ NO		11. INSURED'S DATE OF BIRTH MM DD YY SEX MM DD YY ☐ M ☐ F	
12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below. SIGNED _____ DATE _____		13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize payment of medical benefits to the undersigned physician or supplier for services described below. SIGNED _____	
14. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (LMP) MM DD YY QUAL		15. OTHER DATE MM DD YY QUAL	
16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION FROM MM DD YY TO MM DD YY		17. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES FROM MM DD YY TO MM DD YY	
18. NAME OF REFERRING PROVIDER OR OTHER SOURCE 17a. _____ 17b. NPI 123456789		19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC) INV \$X,XXX.XX 1-Zenith Amniotic Membrane (Q4253) 4cm x 4cm*	
20. OUTSIDE LAB? ☐ YES ☐ NO \$ CHARGES		21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24b) ICD Ind. _____	
22. RESUBMISSION CODE _____ ORIGINAL REF. NO. _____		23. PRIOR AUTHORIZATION NUMBER 123456	
24. A. DATE(S) OF SERVICE From MM DD YY To MM DD YY B. PLACE OF SERVICE C. EMG D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) EPT/HCPCS MODIFIER E. DIAGNOSIS POINTER F. \$ CHARGES G. DAYS OR UNITS H. EPST/PT Family Plan I. ID. QUAL J. RENDERING PROVIDER ID. #			
1 07 15 18 07 15 18 11 Q4253 \$XXX XX 16 NPI			
2 07 15 18 07 15 18 11 15275 \$XXX XX 1 NPI			
3			
4			
5			
6			
25. FEDERAL TAX I.D. NUMBER SSN EIN 01-2345678		26. PATIENT'S ACCOUNT NO. 01234567890	
27. ACCEPT ASSIGNMENT? (For govt. claims, see back) ☐ YES ☐ NO		28. TOTAL CHARGE \$ 29. AMOUNT PAID \$ 30. Rsd. for NUCC Use	
31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.) SIGNED _____ DATE _____		32. SERVICE FACILITY LOCATION INFORMATION a. NPI b. NPI	
33. BILLING PROVIDER INFO & PH# ()			

NUCC Instruction Manual available at: www.nucc.org

PLEASE PRINT OR TYPE

APPROVED CMB-0938-1197 FOR 1500 (02-12)

*Total invoice price is the net amount a provider pays for an item/service, taking into account ALL discounts, rebates, refunds, or other adjustments.

Claim Forms

Insurance Verification Request Form

Patient Insurance Benefit Verification (IBV) Request Form

☐ New patient ☐ Re-verification ☐ Additional applications ☐ New insurance

Sales representative name _____

Patient and Insurance Information

Patient name _____ Date of birth _____

Address _____ City _____ State _____ Zip _____

Is the patient currently residing in a skilled nursing facility? ☐ Yes ☐ No If yes, is the patient covered under a Part A stay? ☐ Yes ☐ No

If patient is currently under a surgical global period, please indicate date and procedure completed

Procedure (CPT) code(s) _____ Date of procedure _____

Primary insurance _____ Policy # _____ Payer phone _____

Secondary insurance _____ Policy # _____ Payer phone _____

Tertiary insurance _____ Policy # _____ Payer phone _____

Workers comp claim # _____ Adjuster name _____ Adjuster phone _____

Physician and Facility Information

Physician name _____ Physician specialty _____

NPI # _____ Medicare (PTAN) provider # _____

Tax ID _____ Medicaid provider # _____

Office contact _____ Phone _____ Fax _____

Treating facility place of service (POS)

☐ Hospital-based outpatient wound department (HOPD – POS 22) ☐ Ambulatory surgery center (ASC – POS 24)

☐ Physician office (POS 11)

☐ Other (please specify, e.g. critical access hospital or POS 19 off-campus or hospice) _____

Facility name _____

Facility address _____ City _____ State _____ Zip _____

NPI # _____ Tax ID _____

Medicare Administrative Contractor (MAC) and Provider ID (PTAN) for claims processing _____

Product and Treatment Information

Product: ☐ (Q4253) Zenith ☐ (Q4262) Impax ☐ (Q4268) SurGraft FT ☐ (Q4276) Orion ☐ (Q4302) Complete ACA ☐ (Q4154) Biovance ☐ (Q4283) Biovance 3L ☐ (Q4296) Rebound

Application codes: 15271 – 15274 for wounds on the trunks, arms, and/or legs

15275 – 15278 for wounds on the face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits

Anticipated treatment start date _____ Number of applications _____ Frequency _____

Total surface area of all wounds _____

Diabetic foot ulcer **Venous leg ulcer** **Pressure ulcer or chronic wound** **Other**

E code _____ I code _____ L code _____

L code _____ L code _____

I certify I have obtained a valid authorization under applicable law from the patient listed on this form (a) permitting me to release the patient's protected health information to Legacy Medical and its contractors to research insurance coverage regarding Legacy Medical products, and to provide me with reimbursement assistance services regarding such products; and (b) authorizing the payer to disclose PHI to Legacy Medical and its contractors for the purposes of verifying insurance and determining benefit coverage.

Provider signature _____

Date _____

Please send form along with a copy of the front and back of patient's insurance card to sunderwood@prodatamgmt.com or fax to (866) 205-0732.

If further assistance is needed, please contact IVR Support Team at (919) 249-7293 for additional support.

Disclaimer: Legacy offers insurance benefit verification service as per product purchase agreement. It is the responsibility of the Provider to provide accurate and complete information as required on the form. Information gathered during verification is provided by the insurer or third-party payer. Verification results do not, in any way, guarantee coverage or reimbursement for Legacy products.

Coverage Summary

Skin Substitute Graft Procedures

The coverage landscape for Skin Substitute Graft Procedures varies by insurance carrier. Please review policies for all payors on a regular basis for updates and changes. Coverage defines what medical technologies, services, medical devices, biologics and procedures a health plan will reimburse, and generally varies by payor. Private health plans, as well as Medicare, may vary in their consideration of coverage for a particular technology, medical device, biologic or procedure. Further, the patient's individual benefit plan will delineate what items and services may be covered by the health plan. It is the provider's and patient's responsibility to verify coverage based upon the patient's health plan, individual plan benefit, and applicable medical necessity criteria.

Case by case pre-authorization approval should be considered following specific payor guidelines for the pre-authorization and appeal process. Please check and confirm the insurer's specific medical policies and pre-authorization guidelines to help facilitate the attainment of coverage. Pre-authorization signifies that the health plan has given a preliminary approval of treatment for that individual patient before the procedure has occurred. Final approval and reimbursement is only provided after the pre-authorized service is delivered, required documentation completed, and submission of the claim for adjudication by the health plan.

Glossary of Reimbursement Terms

Medicare Administrative Contractors (MAC): The Centers for Medicare and Medicaid Services (CMS) contracts with regional Medicare Administrative Contractors (MACs) to administer the Medicare program. Each MAC may establish its own set of guidelines for the coverage of services. When the MAC determines written guidelines are needed these coverage guidelines are published by each MAC as a Local Coverage Determination (LCD).

Coinsurance/Deductibles: Medicare reimburses 80 percent of the allowable amount for most items and services covered under Medicare Part B, including those related to wound care provided in the outpatient setting. The patient, or secondary/supplemental plan, is responsible for the remaining 20 percent coinsurance amount. The appropriate annual deductibles also apply.

APC: Ambulatory Payment Classification

Fee for Service: Medicare reimburses clinicians for application of Zenith Amniotic Membrane as a separate fee from reimbursing for the product itself. Products are reimbursed when purchased by the provider and incident to the physician service. CMS lists for Zenith Amniotic Membrane reimbursement rates on their quarterly ASP Pricing File. CMS requires qualified healthcare providers to bill using the appropriate HCPCS and CPT codes and to accurately report the units of service.

Physician Office (Place of Service – 11): (Location other than a hospital, skilled nursing facility (SNF), military treatment facility, community health center, State or Local public health clinic, or intermediate care facility (ICF), where the health professional routinely provides health examinations, diagnosis, and treatment of illness or injury on an ambulatory basis.)

Ulcer Size: Determining the wound location and surface area is important in order to select the appropriate CPT and ICD-10 codes. Wound size, as measured according to acceptable practice standards, should be documented in the medical record weekly, including the Length (L), Width (W) and Depth (D) in cm.

Supportive Literature

The following literature links may provide additional information about the use of Zenith Amniotic Membrane™ acellular amnion fluid or dehydrated amniotic membrane allograft to support medical necessity.

- Litwiniuk, Malgorzata and Tomasz Grzela. "Amniotic membrane: new concepts for an old dressing". *Wound Repair and Regeneration* 22.4 (2014): 451-456. Access at: <https://onlinelibrary.wiley.com/doi/full/10.1111/wrr.12188>
- Haugh AM, Witt JG, Hauch A, et al. Amnio Membrane in Diabetic Foot Wounds: A Meta-analysis. *Plastic and Reconstructive Surgery Global Open*. 2017; 5(4):e1302. Access at: <http://dx.doi.org/10.1097/GOX.0000000000001302>
- Zelen CM, "An Evaluation of Dehydrated Human Amniotic Membrane Allografts in Patients with DFUs" *J Wound Care* 2013 Jul; 22(7):347-8, 350-1.
- Guo X, Mu D, Gao F. "Efficacy and Safety of acellular dermal matrix in diabetic foot ulcer treatment: A systematic review and meta-analysis. *Int J Surg*. 2017 Apr; 40:1-7 Access at: <https://www.ncbi.nlm.nih.gov/pubmed/28232031>
- Cazzell S, Vayser D. A Randomized Clinical Trial of a Human Acellular Dermal Matrix Demonstrated Superior Healing Rates for Chronic Diabetic Foot Ulcers Over Conventional Care Access at: [Access at: https://www.ncbi.nlm.nih.gov/pubmed/28544150](https://www.ncbi.nlm.nih.gov/pubmed/28544150)
- Cornwell KG, Landsman A. Extracellular Matrix Biomaterials for Soft Tissue Repair. *Clin Podiatric Med Surg*. 2009; Oct; 26(4): 507-23. Access at: <https://www.ncbi.nlm.nih.gov/pubmed/19778685>

Resources for Zenith Amniotic Membrane™ Technology Support

The following resources can provide support when preparing a pre-authorization for the Zenith Amniotic Membrane™ skin substitute graft procedure when performed in the office, outpatient or surgery center setting of care.

These resources have been referenced in this guide and can be provided when required.

- Zenith Amniotic Membrane™ Product Brochures
- Instructions for Use (IFU)

For ICD-10-CM/PCS code mappings access the following links:

- <https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/clm104c17.pdf>
- <https://www.cms.gov/medicare/physician-fee-schedule/search/overview>

The following resources can also provide information to assist providers when procedures and technologies are considered for reimbursement.

- Medicare Physician Fee Schedule Look-up Tool
- National Association of Insurance Commissioners (NAIC) Homepage
- OMHA ALJ Appeal Status Information System (AASIS)

Special Instructions for Hospice Patients – Medicare Requirements

Hospice patients are patients with a terminal illness and who have elected hospice benefits in lieu of standard Medicare coverage for treatment and management of their terminal condition. Different coverage requirements apply as summarized below. The location of treatment may vary, and the below instructions apply depending on whether the physician is a hospice employee or independent and whether the services are related to the terminal condition. For additional information please see CMS Pub. 100-4 Chapter 11.

Professional services related to the hospice patient's terminal condition that are furnished by an independent attending physician are billed to Medicare Part B. When the independent attending physician furnishes a service related to the patient's terminal illness and related conditions that includes both a professional and technical component (e.g., Amniotic membrane or other supply), he/she bills the professional component of such services on a professional claim and looks to the hospice for payment for the technical component.

Any covered Medicare services not related to the treatment of the terminal condition for which hospice care was elected, and which are furnished during a hospice election period, may be billed by the rendering provider using professional or institutional claims for non-hospice Medicare payment.

Use of the below modifiers is required when applicable:

- GV: Attending physician not employed or paid under arrangement by the patient's hospice provider.
- GW: Service not related to the hospice patient's terminal condition.

Please refer to your MAC specific billing guidance for further instructions on the use of these modifiers.

Pre-Authorization

Pre-Authorization Overview

In order to facilitate coverage access for a proposed procedure, the physician may request a pre-authorization from the patient's private insurance carrier. Some health plans require pre-authorization for all surgical procedures. Requesting pre-authorization may only involve a simple contact by the physician's office to verify benefits and acquire an approval number to submit with the claim. Alternatively, pre-authorization may require that the physician provide more substantive information about the case. To prepare a pre-authorization request that requires additional information beyond basic coding, the physician's staff must provide technical information about the procedure and the unique technology involved. The treating physician must also establish the medical necessity for the procedure, as it applies to the specific patient.

Typically, the pre-authorization process and/or appeal process may require submitting some or all of the following documentation:

- Patient clinical notes, including documentation of prior conservative care
- Supporting technical information in the form of the FDA registration letter, peer-reviewed clinical literature, clinical trial information and other available technical resources
- Description of the technology and its use in this patient's case
- Description of medical necessity of the procedure for the specific patient

Documentation Support

The information discussed on the following pages requires obtaining clinical information documented by the clinician treating the patient.

Documentation Support for Prior Authorization

Documentation of a patient's history, conservative therapies and reason for any service or procedure is the key to a positive reimbursement scenario. When a skin substitute graft procedure is indicated by the physician, the patient's medical record should clearly state the reason for the procedure as well as the expected outcomes and recommended therapies to follow. This documentation will support claim review and pre-authorization alike. Follow-up or staged procedures will depend on the initial documentation to support medical necessity. The following general documentation guidelines should be followed for all payors.

Patient visit notes should contain the following details:

- Reason for the procedure based on physical exam
- All conservative therapies previously used in the treatment of the current disease
- Specific reason why this treatment is indicated for this patient
- Anticipated outcomes
- Recommended therapies or treatments
- History of patient encounters including conservative therapies
- Current diagnosis or history of disease state
- Details of findings on exam
- Reason for procedure relevant to condition
- Usual details of procedure
- Explanation of technology specific to Zenith Amniotic Membrane
- Findings and any anticipated further treatments
- Clinical notes should be dated and signed

A letter of medical necessity (LMN) may be required for pre-authorization of a skin substitute graft procedure or for supporting documentation following a request for a claim review. Details of the LMN should include the items on the checklist above. An example LMN is provided in the following section of this guide.

Pre-Authorization

Zenith Amniotic Membrane Pre-Authorization/LMN – Example Letter

PRE-AUTHORIZATION/LETTER OF MEDICAL NECESSITY

Providers, please note: Coverage requirements will typically vary by payor. Therefore, physicians may seek pre-authorization for the procedure, during which time health plans will determine whether the procedure is covered as described in the pre-authorization submission. Providers should select the procedure, diagnosis, and technology coding that best represents each patient's medical condition and treatment and should reflect the services and products that are medically necessary for the treatment of that patient. Providers must ensure that all statements made to insurance carriers are true and correct.

[DATE]

[NAME OF INSURANCE COMPANY]

[ATTN:]

[FAX #:]

RE: [PATIENT NAME]
[INSURANCE IDENTIFICATION NUMBER]
[REFERENCE #:]
[PRIMARY CPT CODE:]
[PRIMARY DX:]

Dear Utilization Review Manager:

On behalf of my patient, [PATIENT NAME], this letter serves as a pre-authorization request and provides clinical information on this patient's condition. It also serves as a formal request for coverage by [INSURANCE COMPANY] for the medically necessary health care services captioned above. This letter and its supporting documents will provide you with a better depiction of this patient's clinical history and this patient's need for the [ZENITH AMNIOTIC MEMBRANE™ SKIN SUBSTITUTE GRAFT PROCEDURE]. It is my sincere hope that this additional information will inform your decision to approve this surgery.

Description of Procedure: [PHYSICIAN INSERTS DETAILED PROCEDURE DESCRIPTION INCLUDING THE USE OF THE ZENITH AMNIOTIC MEMBRANE™ SKIN SUBSTITUTE GRAFT].

Skin Substitute Description: Zenith Amniotic Membrane™ is a dehydrated amniotic membrane allograft intended to be used for homologous use to cover a recipient's tissue. It provides an adhesion barrier for adjacent soft tissues and promotes wound healing. Zenith Amniotic Membrane™ is ready to use and is available in various sizes for improved handling, delivery and optimal coverage.

Key Benefits of Zenith Amniotic Membrane™ Skin Graft Substitute:

- Amniotic membrane expresses immune-privileged antigens
- An immune tolerant graft with negligible risk of foreign body reaction
- Limits the expression of inflammatory cytokines
- Reduces fibrosis, scarring and post-operative pain.

Patient's Clinical Need for the [ZENITH AMNIOTIC MEMBRANE™ Skin Substitute Graft Procedure: [PATIENT NAME] is a [AGE] [GENDER] who presented to me with [DESCRIBE SYMPTOMS WITH SPECIFICITY]. Prior treatments have included [DESCRIBE CONSERVATIVE CARE, USE OF MEDICATIONS, PRIOR TREATMENTS, and PHYSICAL AIDS].

In a discussion with [INSERT MR/MS] following an exam, a decision was made to move forward with a skin substitute graft procedure. The amniotic and placental properties of [ZENITH AMNIOTIC MEMBRANE™ SKIN SUBSTITUTE GRAFT] allows for easy application, making it a flexible, dependable option for wound and soft tissue healing for my patient.

Should you have further questions or concerns, please do not hesitate to call me at [INSERT PHYSICIAN TELEPHONE NUMBER]. Thank you for your immediate attention and anticipated authorization of these services for your insured.

Sincerely,

[PHYSICIAN NAME], [DEGREE]

Plan Denial Appeal Process

Plan Denial Appeal Process Overview

When a third-party health plan denies a procedure in accordance with their medical policy guidelines, there is a process available to appeal that decision whether the denial is a prior authorization denial or denial of a claim submitted for reimbursement. Insurance carriers provide this check and balance to allow for reconsideration of the decision per their plan provisions and applicable state regulations. The process will vary depending on the plan and regulatory requirements; however, there are basic steps that can assist the provider in appealing the initial denial.

To file an appeal, it is recommended to follow these steps:

1. Carefully review the denial reason and understand the specific health plan's policy.
2. Write an appeal letter clearly addressing the specific denial reasons.
3. Provide supporting information including product details and FDA registration; and
4. Submit the appeal on time.

The following additional considerations may be helpful:

1. If the health plan is self-funded (employer based), patients can contact their Human Resources (HR) department to assist in the patient's appeal of the decision. HR departments may have contacts within the health plan that can provide helpful support.
2. The patient can contact the health plan directly and is the policyholder with an influence on the decision.
3. There are multiple steps in the appeal process and providers and patients may exercise these rights according to their third-party payor and state guidelines.

Writing the Appeal Letter

When appealing a denial, the first step is often composing a letter to the health plan that initially reviewed the case. This letter is submitted by the provider on behalf of the patient, with the patient's approval, and should outline the reasons the denial should be overturned.

Detailed information regarding the denial reason should be prepared utilizing the case specific information in the denial, as well as the more general technology specific information and supporting clinical literature.

First, collect all the information required to support the appeal:

- Denial letter / denial reason
- Health plan contracts and provider agreements
- Applicable medical policy guidelines from the health plan (website access is often a good resource for general policy)
- Literature supporting the technology
- FDA registration letter
- Safety and effectiveness documentation
- Peer-reviewed literature references (when available)

In drafting an appeal letter, consider the following:

- Did the reviewer overlook a case specific detail?
- Does the health plan clearly understand the procedure?
- Was the information provided about the case correctly submitted?
- Review the plan's official policy online for more detailed understanding of the denial reason

Plan Denial Appeal Process

Zenith Amniotic Membrane PA Denial Appeal – Example Letter

ZENITH AMNIOTIC MEMBRANE PRE-AUTHORIZATION APPEAL LETTER

***Providers, please note:** Despite the filing of a pre-authorization request, certain commercial health plans may still elect not to cover or grant pre-authorization for this procedure without further information and clinical evidence supporting its use. Should pre-authorization be denied, the physician requesting coverage should immediately file a written appeal with the health plan and request reconsideration of the coverage decision. When requesting a pre-authorization appeal it is important to remember that payors may require all elements of a procedure to be pre-authorized per their payor guidelines. To assist you, the following example is offered as a starting point for your pre-authorization denial appeal and reconsideration request.*

[DATE]
[NAME OF INSURANCE
COMPANY] [ATTN:]
[FAX #:]

RE: [PATIENT NAME]
[INSURANCE IDENTIFICATION
NUMBER] [REFERENCE #:]
[PRIMARY
CPT CODE]
[PRIMARY DX
CODE]

Dear Utilization Review Manager:

Please accept this letter on behalf of [PATIENT NAME], as an appeal to [INSURANCE COMPANY]'s decision to deny coverage for the recommended [PROCEDURE]. It is my understanding, per [INSURANCE COMPANY]'s denial letter dated [INSERT DENIAL LETTER DATE], that this procedure has been denied because [REASON FOR DENIAL].

I respectfully request that [INSURANCE COMPANY] reconsider its denial and provide authorization for this treatment option. I believe this denial was made in error. This letter and its supporting documents will provide you with a better depiction of this patient's clinical history and this patient's need for the [ZENITH AMNIOTIC MEMBRANE SKIN SUBSTITUTE GRAFT PROCEDURE]

Description of Procedure: [PHYSICIAN INSERTS DETAILED PROCEDURE DESCRIPTION INCLUDING THE USE OF THE [ZENITH AMNIOTIC MEMBRANE SKIN SUBSTITUTE GRAFT PROCEDURE]

Skin Substitute Description: Zenith Amniotic Membrane™ is a dehydrated amniotic membrane allograft intended to be used for homologous use to cover a recipient's tissue. It provides an adhesion barrier for adjacent soft tissues and promotes wound healing.

Zenith Amniotic Membrane™ is ready to use and is available in various sizes for improved handling, delivery and optimal coverage. The strength of the allograft allows for suturing in place and no bulk at the surgical site.

Key Benefits of Zenith Amniotic Membrane™ Skin Graft Substitute:

- Amniotic membrane expresses immune-privileged antigens
- An immune tolerant graft with negligible risk of foreign body reaction
- Limits the expression of inflammatory cytokines
- Contain large amounts of hyaluronic acid that entrap inflammatory cells.

[ZENITH AMNIOTIC MEMBRANE] is regulated by the U.S. Food and Drug Administration (FDA) as a human skin tissue under its Human Cells, Tissues, and Tissue-Based Products (HCT/P) guidelines, subject to Section 361 of the Public Health Service Act and 21 CFR 1270 and 1271.

(continued on next page)

Plan Denial Appeal Process

Zenith Amniotic Membrane PA Denial Appeal – Example Letter (continued)

[ZENITH AMNIOTIC MEMBRANE] is an appropriate clinical option in the treatment of chronic, non-infected, partial or full thickness diabetic lower extremity ulcers; chronic, non-infected, full thickness diabetic lower extremity skin ulcers due to venous insufficiency which have not adequately responded following conventional ulcer therapy; second- or third-degree burns.

Please consider the following references in support of [ZENITH AMNIOTIC MEMBRANE] procedures:

- Litwiniuk, Malgorzata and Tomasz Grzela. “Amniotic membrane: new concepts for an old dressing”. *Wound Repair and Regeneration* 22.4 (2014): 451-456. Access at: <https://onlinelibrary.wiley.com/doi/full/10.1111/wrr.12188>
- Haugh AM, Witt JG, Hauch A, et al. Amnio Membrane in Diabetic Foot Wounds: A Meta-analysis. *Plastic and Reconstructive Surgery Global Open*. 2017; 5(4):e1302. Access at: <http://dx.doi.org/10.1097/GOX.0000000000001302>
- Zelen CM, “An Evaluation of Dehydrated Human Amniotic Membrane Allografts in Patients with DFUs” *J Wound Care* 2013 Jul; 22(7):347-8, 350-1.

Patient’s Clinical Need for the [ZENITH AMNIOTIC MEMBRANE]

Skin Substitute Graft Procedure: [PATIENT NAME] is a [AGE] [GENDER] who presented to me with [DESCRIBE SYMPTOMS WITH SPECIFICITY]. Prior treatments have included [DESCRIBE CONSERVATIVE CARE, USE OF MEDICATIONS, PRIOR TREATMENTS, and PHYSICAL AIDS].

To assist in your reconsideration of this patient’s clinical need for the intended procedure, a copy of the relevant clinical notes that support use of the [ZENITH AMNIOTIC MEMBRANE SKIN SUBSTITUTE GRAFT] is enclosed to support you with your decision to overturn your initial denial of coverage for these services. It is my sincere hope that [INSURANCE COMPANY] will respond with a positive decision so that [PATIENT NAME] can benefit from the results of this procedure. Should you have further questions or concerns, please do not hesitate to call me at [INSERT PHYSICIAN TELEPHONE NUMBER].

Thank you for your immediate attention and reconsideration.

Sincerely,

[PHYSICIAN NAME],
[DEGREE] [PRACTICE]
[NPI NUMBER]

References

1. CMS Manual for that detail Section 20.1.3: <https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/clm104c17.pdf>
2. AMA CPT® 2024
3. <https://www.cms.gov/medicare/physician-fee-schedule/search/overview>

CPT® only copyright 2024 American Medical Association. All rights reserved.

For more details, please contact our corporate office



LEGACY MEDICAL
CONSULTANTS

(817) 961-1288

www.legacymedicalconsultants.com

customerservice@legacymedicalconsultants.com